Clinical trial
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat…
NCT00390221 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00390221 |
|---|---|
| Title | Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis |
| Official title | Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis |
| Acronym | SELECT |
| Lead sponsor | Biogen, Industry |
| Collaborators | AbbVie Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsing-Remitting Multiple Sclerosis |
| Intervention type | Biological, Drug |
| Interventions | BIIB019 (Daclizumab High Yield Process), Placebo |
| Enrollment | 621 |
| Start date | Feb 1, 2008 |
| Primary completion | May 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Oct 19, 2006 |
| Last update posted | Jul 11, 2016 |
| Countries | Czechia, Germany, Hungary, India, Poland, Russia, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: